Wearable device data may help detect and track idiopathic pulmonary arterial hypertension, a rare lung disease, a study ...
The first participant has been enrolled in a two-part Phase 3 clinical trial testing IKT-001, an experimental treatment for ...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...
View all available purchase options and get full access to this article. Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, Givertz MM, Felker GM, LeWinter MM, Mann DL, et al; National ...
Abstract: Pulmonary hypertension (PH) is a fatal pulmonary vascular disease. The standard diagnosis of PH heavily relies on an invasive technique, i.e., right heart catheterization, which leads to a ...
Pulmonary hypertension is a condition where specialist input is essential, yet the day-to-day management of many patients takes place in local hospitals, usually in general respiratory clinics, far ...
Pulmonary hypertension (PH) is a progressive disease marked by pulmonary arterial remodeling and right ventricular dysfunction. The molecular mechanisms driving this remodeling, particularly ECM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results